静脉注射免疫球蛋白治疗阿尔茨海默病的3期试验
这项3期双盲安慰剂对照试验将390例轻中度阿尔茨海默病痴呆患者随机分配接受安慰剂(低剂量白蛋白)或IVIg(0.2或0.4 g/kg,每2周一次,共18个月)。结果显示两种IVIg剂量在双重主要结局(认知与功能)上均无获益,但IVIg组血浆Aβ42显著下降,安全性方面无淀粉样蛋白相关影像异常差异。
要点
- IVIg每2周一次治疗18个月对轻中度AD患者的认知和功能均无改善。
- IVIg治疗可显著降低血浆Aβ42水平,但未转化为临床获益。
- IVIg组全身反应(寒战、皮疹)更多,但呼吸道感染更少。
核心结论
- 轻中度AD患者对低剂量人IVIg治疗18个月耐受性良好,但认知和功能结局与安慰剂组相比无获益。
研究设计与样本
- 3期双盲安慰剂对照试验,390例轻中度AD患者随机接受安慰剂(低剂量白蛋白)或IVIg 0.2或0.4 g/kg,每2周一次,共18个月。
主要发现
- 两种IVIg剂量在双重主要结局指标上均未观察到有益效应。
- IVIg治疗组血浆Aβ42水平显著下降,但Aβ40无显著变化。
- IVIg与安慰剂在淀粉样蛋白相关影像异常(脑水肿或微出血)发生率上无差异。
- IVIg组全身反应(寒战、皮疹)更多,但呼吸道感染更少。
关键数值与推荐
- 主要认知结局为阿尔茨海默病评估量表11项认知子量表从基线至18个月的变化。
- 主要功能结局为阿尔茨海默病协作研究-日常生活活动量表18个月的变化。
- IVIg剂量为0.2或0.4 g/kg,每2周静脉给药一次,持续18个月。
临床怎么用
- 不推荐对轻中度AD患者使用IVIg以改善认知或功能。
- IVIg治疗期间需关注全身反应(寒战、皮疹),但呼吸道感染风险可能较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We tested biweekly infusions of IV immunoglobulin (IVIg) as a possible treatment for mild to moderate Alzheimer disease (AD) dementia. METHODS: In a phase 3, double-blind, placebo-controlled trial, we randomly assigned 390 participants with mild to moderate AD to receive placebo (low-dose albumin) or IVIg (Gammagard Liquid; Baxalta, Bannockburn, IL) administered IV at doses of 0.2 or 0.4 g/kg every 2 weeks for 18 months. The primary cognitive outcome was change from baseline to 18 months on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale; the primary functional outcome was 18-month change on the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory. Safety and tolerability data, as well as serial MRIs and plasma samples, were collected throughout the study from all enrolled participants. RESULTS: No beneficial effects were observed in the dual primary outcome measures for the 2 IVIg doses tested. Significant decreases in plasma Aβ42 (but not Aβ40) levels were observed in IVIg-treated participants. Analysis of safety data showed no difference between IVIg and placebo in terms of the rate of occurrence of amyloid-related imaging abnormalities (brain edema or microhemorrhage). IVIg-treated participants had more systemic reactions (chills, rashes) but fewer respiratory infections than participants receiving placebo. CONCLUSIONS: Participants with mild to moderate AD showed good tolerability of treatment with low-dose human IVIg for 18 months but did not show beneficial effects on cognition or function relative to participants who received placebo. CLINICALTRIALSGOV IDENTIFIER: NCT00818662. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that IVIg infusions performed every 2 weeks do not improve cognition or function at 18 months in patients with mild to moderate AD.
引用
- Relkin NR, Thomas RG, Rissman RA, et al. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017. PMID: 28381506. doi:10.1212/WNL.0000000000003904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。